Physician profile
Christopher Preston Daniel
NPI 1881135770
$1,312.63
in general payments reported to CMS, 2019-2025
18 companies · $178 in 2025
The $178 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $102 · 2022: $506 · 2023: $204 · 2024: $323 · 2025: $178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $705.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $704.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $265.01 | 2021-2025 | Austedo, Austedo Xr, Uzedy |
| Otsuka America Pharmaceutical, INC. | $186.57 | 2021-2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $160.42 | 2024 | Invega Sustenna |
| Indivior INC. | $124.85 | 2021-2025 | Sublocade |
| Abbvie INC. | $110.92 | 2021-2024 | |
| Ironshore Pharmaceuticals INC. | $101.68 | 2022-2023 | Jornay Pm |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $70.08 | 2022 | |
| Vanda Pharmaceuticals INC. | $53.30 | 2021-2023 | Fanapt, Hetlioz |
| E.R. Squibb & Sons, L.L.C. | $48.50 | 2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $42.43 | 2023-2024 | Caplyta |
| Alkermes, INC. | $31.28 | 2022-2023 | Vivitrol |
| Braeburn INC. | $22.04 | 2025 | Brixadi |
| Neurocrine Biosciences, INC. | $18.67 | 2025 | |
| Lundbeck LLC | $17.44 | 2022 | |
| Luye Pharma (USA) LTD. | $15.65 | 2025 | Erzofri Extended-Release |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $15.32 | 2023 | Loreev Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $14.54 | 2023 | Trintellix |
| Avanir Pharmaceuticals, INC. | $13.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Daniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.